Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen (AMGN) today and set a price target of $200.00. The company’s shares closed last Friday at $239.64.
According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.5% and a 41.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $243.69, a 4.0% upside from current levels. In a report issued on April 28, Leerink Partners also initiated coverage with a Hold rating on the stock with a $230.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $276.69 and a one-year low of $210.28. Currently, Amgen has an average volume of 2.68M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
